Beijing Normal University presented data on fibroblast activation protein (FAP)-targeting agents containing a nitroimidazole moiety, [68Ga]/[177Lu]AAZTA-NI-FAPI-04, being developed for the potential ...

Aberrant expression of G9a and NSD2 has been identified in multiple types of cancer. Therefore, dual-target inhibitors blocking both pathways may be considered a potential strategy to treat solid ...

10月11日，CDE官网显示，恒瑞医药的EZH2抑制剂SHR2554片申报上市。这是首个申报上市的国产EZH2抑制剂。 SHR2554是恒瑞医药自主研发的新型、高效、选择 ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.